Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-37

"Two things to add in: costs of the CLBP trial and paying back debt"
Start up for CLBP would have been paid. I would anticipate a decline in costs of CLBP trial over the next 12 months. Paying back debt, probably 10 million. We have already made one payment of 10 million, that had the effect of reducing the requirement of holding 35 million in available cash too 25 million. So net effect on MSBs available reserves were 0.

We have at least 3 quarters left. We need however a better run way if by chance the FDA turn negative. That is why I think we will see a financial deal been made for a additional 100 million.
It would cost 5 or perhaps 10 million dollars but would avoid a CR like last time. That cash run way would give us just under 3 years of funding.